세계의 항감염증약 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Anti-Infective Agents Market is presumed to reach the market size of nearly USD 203.86 Billion by 2032 from USD 174.7 Billion in 2023 with a CAGR of 1.73% under the study period 2024-2032.

Anti-infective agents are medications used to prevent and treat infections caused by various pathogens, including viruses, bacteria, fungi, and parasites. They include antibiotics, antivirals, antifungals, and antiparasitic drugs. These agents work by inhibiting the growth of or killing infectious organisms. The choice of anti-infective agent depends on the type of infection, the causative pathogen, and the patient's health condition. Proper use of these agents is essential to prevent the development of resistance, ensure effective treatment of infections, and safeguard public health.

MARKET DYNAMICS

The rising incidence of bacterial, viral, fungal, and parasitic infections necessitates the development and availability of effective anti-infective agents. Advances in medical research have led to the creation of novel antibiotics, antivirals, antifungals, and antiparasitics, addressing resistant strains and improving treatment outcomes. The growing awareness of the importance of early and appropriate infection treatment also boosts demand. Additionally, expanding healthcare infrastructure in developing regions and increasing accessibility to healthcare services play crucial roles. Supportive government initiatives and funding for infectious disease research further stimulate the market. The increasing occurrence of hospital-acquired infections underscores the need for effective anti-infective agents. Pharmaceutical companies' investment in R&D, strategic partnerships, and collaborations for drug development accelerate the introduction of new and advanced anti-infective agents, driving market growth. However, the emergence of resistant strains and side effects of treatments may challenge market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anti-Infective Agents. The growth and trends of Anti-Infective Agents industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Anti-Infective Agents market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type/Drug Class

• Antibacterials (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others)
• Antivirals
• Antifungals (Azoles, Echinocandins, Polyenes, Others)

By Route of Administration

• Topical
• Oral
• IV
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• E-Commerce
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anti-Infective Agents market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anti-Infective Agents market include Pfizer Inc., Abbott, Gilead Sciences Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Sandoz International GmbH, B. Braun SE, Xellia Pharmaceuticals, Mankind Pharma, Bayer AG, AstraZeneca, Boehringer Ingelheim International GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ANTI-INFECTIVE AGENTS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type/Drug Class
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTI-INFECTIVE AGENTS MARKET ANALYSIS BY TYPE/DRUG CLASS

• 5.1. Overview By Type/Drug Class
• 5.2. Historical and Forecast Data Analysis By Type/Drug Class
• 5.3. Antibacterials (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others) Historic and Forecast Sales By Regions
• 5.4. Antivirals Historic and Forecast Sales By Regions
• 5.5. Antifungals (Azoles, Echinocandins, Polyenes, Others) Historic and Forecast Sales By Regions

6. GLOBAL ANTI-INFECTIVE AGENTS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1. Overview By Route of Administration
• 6.2. Historical and Forecast Data Analysis By Route of Administration
• 6.3. Topical Historic and Forecast Sales By Regions
• 6.4. Oral Historic and Forecast Sales By Regions
• 6.5. IV Historic and Forecast Sales By Regions
• 6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL ANTI-INFECTIVE AGENTS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
• 7.4. Retail Pharmacies Historic and Forecast Sales By Regions
• 7.5. Specialty Pharmacies Historic and Forecast Sales By Regions
• 7.6. E-Commerce Historic and Forecast Sales By Regions
• 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ANTI-INFECTIVE AGENTS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ANTI-INFECTIVE AGENTS COMPANIES

• 9.1. Anti-Infective Agents Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF ANTI-INFECTIVE AGENTS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Pfizer Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Abbott
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Gilead Sciences Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Bristol-Myers Squibb Company
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Merck & Co. Inc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Sandoz International GmbH
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. B. Braun SE
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Xellia Pharmaceuticals
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Mankind Pharma
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Bayer AG
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. AstraZeneca
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Boehringer Ingelheim International GmbH
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies